ADXN · Addex Therapeutics Ltd. · Shareholders & Ownership
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Every disclosed holder of ADXN in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns ADXN
13F quarter Sep 30, 2026, combined view: filers that have not filed yet carry their Jun 30, 2026 positionsNo chart: shares outstanding cannot be set against these holders.
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 188 | — |
| Insiders (Forms 3, 4, 5) | 22,254,361 | — |
| 13D/G-only blocks | 6,624,600 | — |
| Registered funds (N-PORT, not summed) | 0 | — |
% Out is unavailable: a foreign private issuer reports ordinary shares, a different unit from the listed shares.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of ADXN
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
|
19,165,714 | ||
| 1.1 |
Dyer Timothy Mark
Insider
CIK 1830908 · Sep 2, 2026
Director, Chief Executive Officer, 10% Owner, issuer-wide
|
16,848,979 | ||
| 2 |
Growth Equity Opportunities Fund IV, LLC
13D
CIK 1644965 · Unknown · Aug 1, 2024
unconfirmed, last confirmed Aug 1, 2024
|
6,624,600 | ||
| 3 |
|
2,507,987 | ||
| 4 |
|
1,365,532 | ||
| 5 |
|
785,976 | ||
| 6 |
|
306,765 | ||
| 7 |
|
219,561 | ||
| 8 |
|
219,561 | ||
| 9 |
SBI Securities Co., Ltd.
13F
CIK 1851815 · Non-US institution · Sep 30, 2026
|
141 | ||
| 10 |
|
47 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.